Clinical trial data sharing has massive potential for catalysing scientific innovation.
Investors who see early-stage compounds and indications as valuable assets can support them to market.
10/03/2017February 8, 2017
Balancing innovation and huge unmet patient need with burgeoning cost constraints.
Pharma must be prepared to work collaboratively to establish the best benefit-risk profiles and outcomes.